4,101 reports of this reaction
3.2% of all IBRUTINIB reports
#4 most reported adverse reaction
DIARRHOEA is the #4 most commonly reported adverse reaction for IBRUTINIB, manufactured by Pharmacyclics LLC. There are 4,101 FDA adverse event reports linking IBRUTINIB to DIARRHOEA. This represents approximately 3.2% of all 129,122 adverse event reports for this drug.
Patients taking IBRUTINIB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among IBRUTINIB users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for IBRUTINIB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 4,101 FDA reports for IBRUTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.2% of all adverse event reports for IBRUTINIB, making it a notable side effect.
If you experience diarrhoea while taking IBRUTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.